All Updates

All Updates

icon
Filter
M&A
Recursion Pharmaceuticals and Exscientia enters definitive merger agreement to combine portfolios and create complementary synergy
Longevity Tech
Aug 8, 2024
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Today
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Today
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Today
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Yesterday
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Yesterday
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Yesterday
Partnerships
FinFit partners with Sunny Day Fund to offer emergency savings accounts
Financial Wellness Tools
Yesterday
Partnerships
KSP partners with Peak Technologies and Locus Robotics for warehouse automation
Logistics Tech
Yesterday
Longevity Tech

Longevity Tech

Aug 8, 2024

Recursion Pharmaceuticals and Exscientia enters definitive merger agreement to combine portfolios and create complementary synergy

M&A

  • Recursion Pharmaceuticals and Exscientia have entered a definitive merger agreement. Integrating Exscientia's precision oncology pipeline with Recursion's pipeline, which spans rare diseases, precision oncology, and infectious diseases, is expected to create a complementary synergy.

  • Upon integration, the companies expect that the enhanced and expanded Recursion OS will facilitate the discovery and translation of higher-quality medicines more efficiently and on a larger scale. Additionally, the combined entity expects to deliver results from approximately 10 clinical trials over the next 18 months.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.